Rapid CommunicationComparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysisQiu, Mei MS*; Ding, Liang-Liang MS†; Wei, Xu-Bin MS‡; Liu, Shu-Yan MS§; Zhou, Hai-Rong MD*Author Information *Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China; †Department of Endocrinology, First Affiliated Hospital of Yangtze University, Jingzhou, China; and Departments of ‡Cardiology, and §Endocrinology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China. Reprints: Hai-Rong Zhou, MD, Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China (e-mail: [email protected]). The authors report no conflicts of interest. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jcvp.org). Journal of Cardiovascular Pharmacology: January 2021 - Volume 77 - Issue 1 - p 34-37 doi: 10.1097/FJC.0000000000000916 Buy SDC Metrics Abstract The comparative efficacy of different glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events (MACE) in type 2 diabetes with or without cardiorenal disease is undefined. PubMed and Embase were searched for relevant randomized trials. We conducted network meta-analysis within the Bayesian framework. Effect sizes were measured using hazard ratio (HR) and 95% confidence interval (CI). We calculated surface under the cumulative ranking curve (SUCRA) values to rank drug interventions for different type 2 diabetic subgroups. Albiglutide (HR 0.76, 95% CI 0.63–0.93) and subcutaneous semaglutide (HR 0.71, 95% CI 0.52–0.95), with the maximum SUCRA values, significantly reduced MACE versus lixisenatide in people with diabetes with cardiovascular disease; albiglutide (HRs: 0.69 and 0.72), with the maximum SUCRA value, significantly reduced MACE versus dapagliflozin and exenatide in people with diabetes with heart failure; and canagliflozin (HRs: 0.72 and 0.72) and liraglutide (HRs: 0.68 and 0.68), with the maximum SUCRA values, significantly reduced MACE versus exenatide and lixisenatide in people with diabetes with chronic kidney disease. In preventing MACE in type 2 diabetes, subcutaneous semaglutide and albiglutide are most effective for diabetes with cardiovascular disease, albiglutide is most effective for diabetes with heart failure, and canagliflozin and liraglutide are most effective for diabetes with chronic kidney disease. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.